Giovanna T. Stein

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Sandra Misale, Jackson P. Fatherree, Eliane Cortez et al. · Clinical Cancer Research · 2018 · 267 citations

Medicine, Oncology, Pharmacology +14

Differential Effector Engagement by Oncogenic KRAS

Tina L. Yuan, Arnaud Amzallag, Rachel Bagni et al. · Cell Reports · 2018 · 149 citations · Full text

Medicine, Molecular Biology, Oncology +16

Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression

Timothy L. Lochmann, Konstantinos V. Floros, Mitra Naseri et al. · Clinical Cancer Research · 2017 · 130 citations · Full text

Medicine, Cancer Biology, Pharmacology +15

The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity

Daniel A.R. Heisey, Timothy L. Lochmann, Konstantinos V. Floros et al. · Clinical Cancer Research · 2018 · 40 citations

Medicine, Oncology, Pharmacology +15

Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i> -amplified neuroblastoma

Krista M. Dalton, Timothy L. Lochmann, Konstantinos V. Floros et al. · Proceedings of the National Academy of Sciences · 2021 · 23 citations · Full text

Medicine, Cancer Biology, Oncology +17